Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_4
1
33%
Ph not_applicable
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Enrolling by invitation1
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

enrolling_by_invitation133%
not_yet_recruiting133%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_4

A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy

NCT07091994
enrolling_by_invitationnot_applicable

Promoting Motivation and Linguage in Developmental Language Disorder Through Interaction With the Humanoid Social Robot

NCT07426328
withdrawnphase_2

Cri Analog PG1 Effectiveness and Safety in Covid-19

NCT04536363

Clinical Trials (3)

Showing 3 of 3 trials
NCT07091994Phase 4

A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy

Not Yet Recruiting
NCT07426328Not Applicable

Promoting Motivation and Linguage in Developmental Language Disorder Through Interaction With the Humanoid Social Robot

Enrolling By Invitation
NCT04536363Phase 2

Cri Analog PG1 Effectiveness and Safety in Covid-19

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3